238 related articles for article (PubMed ID: 27238746)
1. Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.
Komers R; Xu B; Schneider J; Oyama TT
Br J Pharmacol; 2016 Sep; 173(17):2573-88. PubMed ID: 27238746
[TBL] [Abstract][Full Text] [Related]
2. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Lee HJ; Jeong KH; Kim YG; Moon JY; Lee SH; Ihm CG; Sung JY; Lee TW
Am J Nephrol; 2014; 40(1):56-63. PubMed ID: 25034030
[TBL] [Abstract][Full Text] [Related]
3. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Mizuno Y; Yamamotoya T; Nakatsu Y; Ueda K; Matsunaga Y; Inoue MK; Sakoda H; Fujishiro M; Ono H; Kikuchi T; Takahashi M; Morii K; Sasaki K; Masaki T; Asano T; Kushiyama A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546603
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.
Shirakura T; Nomura J; Matsui C; Kobayashi T; Tamura M; Masuzaki H
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):831-8. PubMed ID: 27198514
[TBL] [Abstract][Full Text] [Related]
5. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Omizo H; Tamura Y; Morimoto C; Ueno M; Hayama Y; Kuribayashi-Okuma E; Uchida S; Shibata S
Sci Rep; 2020 Jun; 10(1):9326. PubMed ID: 32518351
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway.
Yang KJ; Choi WJ; Chang YK; Park CW; Kim SY; Hong YA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835220
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Fahmi AN; Shehatou GS; Shebl AM; Salem HA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):819-30. PubMed ID: 27215580
[TBL] [Abstract][Full Text] [Related]
8. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.
Kosugi T; Nakayama T; Heinig M; Zhang L; Yuzawa Y; Sanchez-Lozada LG; Roncal C; Johnson RJ; Nakagawa T
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F481-8. PubMed ID: 19458127
[TBL] [Abstract][Full Text] [Related]
9. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
10. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Tsuda H; Kawada N; Kaimori JY; Kitamura H; Moriyama T; Rakugi H; Takahara S; Isaka Y
Biochem Biophys Res Commun; 2012 Oct; 427(2):266-72. PubMed ID: 22995295
[TBL] [Abstract][Full Text] [Related]
12. Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Xu D; Murakoshi N; Tajiri K; Duo F; Okabe Y; Murakata Y; Yuan Z; Li S; Aonuma K; Song Z; Shimoda Y; Mori H; Sato A; Nogami A; Aonuma K; Ieda M
Clin Sci (Lond); 2021 Oct; 135(20):2409-2422. PubMed ID: 34386810
[TBL] [Abstract][Full Text] [Related]
13. The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats.
Kim HS; Lim SW; Jin L; Jin J; Chung BH; Yang CW
Nephron; 2017; 135(1):61-71. PubMed ID: 27701176
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
[TBL] [Abstract][Full Text] [Related]
15. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
16. Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake-Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats.
Namai-Takahashi A; Sakuyama A; Nakamura T; Miura T; Takahashi J; Kurosawa R; Kohzuki M; Ito O
Am J Hypertens; 2019 Jan; 32(1):26-33. PubMed ID: 30277494
[TBL] [Abstract][Full Text] [Related]
17. [Effects and mechanisms of huangkui capsule ameliorating renal fibrosis in diabetic nephropathy rats via inhibiting oxidative stress and p38MAPK signaling pathway activity in kidney].
Mao ZM; Wan YG; Sun W; Chen HL; Huang YR; Shi XM; Yao J
Zhongguo Zhong Yao Za Zhi; 2014 Nov; 39(21):4110-7. PubMed ID: 25775777
[TBL] [Abstract][Full Text] [Related]
18. Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats.
Rai U; Kosuru R; Prakash S; Tiwari V; Singh S
Eur J Pharmacol; 2019 Dec; 865():172763. PubMed ID: 31682792
[TBL] [Abstract][Full Text] [Related]
19. Ursolic acid improves diabetic nephropathy via suppression of oxidative stress and inflammation in streptozotocin-induced rats.
Xu HL; Wang XT; Cheng Y; Zhao JG; Zhou YJ; Yang JJ; Qi MY
Biomed Pharmacother; 2018 Sep; 105():915-921. PubMed ID: 30021385
[TBL] [Abstract][Full Text] [Related]
20. β-N-Oxalyl-L-α,β-diaminopropionic acid from Panax notoginseng plays a major role in the treatment of type 2 diabetic nephropathy.
Li J; Qiu P; Wang S; Wu J; He Q; Li K; Xu L
Biomed Pharmacother; 2019 Jun; 114():108801. PubMed ID: 30928803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
